TENET HEALTHCARE CORP
Cantor Fitzgerald reaffirmed its Overweight rating on Tenet Healthcare (NYSE:THC) with a $270 price target, citing stable labor conditions and strong financial performance. The stock has gained 36% in six months and trades at a P/E ratio of 10.16. Other analysts have also raised price targets, while BMO Capital initiated coverage with a Market Perform rating. A director's share sale was recently disclosed.
The FTC sent letters to 24 major healthcare companies, including HCA Healthcare, Tenet Healthcare, Community Health Systems, and Universal Health Services, warning them to provide accurate and timely pricing information to patients. The FTC emphasized that deceptive pricing practices are prohibited, and companies must comply with transparency regulations.
Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning THC (TENET HEALTHCARE CORP). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent THC coverage spans financial news, corporate actions and regulation.
In the last 30 days, THC insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($5.8M). The most active reporter was KERREY J ROBERT with 3 filings.
Analyst upgrades suggest upside, but insider sale adds slight downside pressure.
Tenet faces regulatory risk that could affect its valuation.
Refinancing reduces near‑term debt burden and may improve credit metrics, supporting the stock's recent rally.
Analyst reaffirmation may provide modest upside support.
Target price cut suggests weaker outlook, likely prompting sell pressure.
AlphAI scores every news story that mentions THC with an AI model for sentiment and relevance, and aggregates insider trades from TENET HEALTHCARE CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cantor Fitzgerald reaffirmed its Overweight rating on Tenet Healthcare (NYSE:THC) with a $270 price target, citing stable labor conditions and strong financial performance. The stock has gained 36% in six months and trades at a P/E ratio of 10.16. Other analysts have also raised price targets, while BMO Capital initiated coverage with a Market Perform rating. A director's share sale was recently disclosed.
2 min readThe FTC sent letters to 24 major healthcare companies, including HCA Healthcare, Tenet Healthcare, Community Health Systems, and Universal Health Services, warning them to provide accurate and timely pricing information to patients. The FTC emphasized that deceptive pricing practices are prohibited, and companies must comply with transparency regulations.
1 min readTenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.
2 min readCantor Fitzgerald maintained an Overweight rating on Tenet Healthcare (THC) with a $270 price target, citing strong 2027 visibility and attractive valuation. Analysts highlight inpatient volume outlooks and quantified headwinds. Recent upgrades from Raymond James, UBS, and Guggenheim contrast with BMO's Market Perform rating. Director Richard Mark sold 10,000 shares at $263.42 each.
1 min readArgus lowered its target price for Tenet Healthcare (THC) to $283.00. The company operates 47 hospitals and over 500 outpatient facilities in the US, mainly in the South. This update may impact investor expectations for THC's stock performance.
1 min readTenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.
2 min readTenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.
3 min readBMO Capital initiated coverage on Tenet Healthcare (NYSE:THC) with a Market Perform rating and a $265 price target. The firm cited favorable long-term trends in its ambulatory surgery center business and operational improvements. Tenet's stock trades at a P/E ratio of 10.25 and a PEG ratio of 0.15, with analysts noting potential undervaluation. Recent upgrades from Raymond James, UBS, Cantor Fitzgerald, and Guggenheim followed strong financial performance.
2 min readTENET HEALTHCARE CORP (THC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth below in Item 2.03 is incorporated by reference into this Item 1.01. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On S
2 min readTenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.
3 min read
